Endo Says FTC Needs Permission To Pull Pay-For-Delay Suit
Endo Pharmaceuticals Inc. on Monday found itself in the unusual position of arguing to keep open the U.S. Federal Trade Commission's pay-for-delay suit against the company over pain drugs Opana ER...To view the full article, register now.
Already a subscriber? Click here to view full article